tetano
Editor, Senior Moderator
Vaccine
. 2023 Jun 27;S0264-410X(23)00780-6.
doi: 10.1016/j.vaccine.2023.06.077. Online ahead of print. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
Seontae Kim[SUP] 1 [/SUP], Mijeong Ko[SUP] 2 [/SUP], Yesul Heo[SUP] 2 [/SUP], Yeon-Kyeng Lee[SUP] 2 [/SUP], Yunhyung Kwon[SUP] 2 [/SUP], Seok-Kyoung Choi[SUP] 2 [/SUP], Eunok Bahng[SUP] 2 [/SUP]
Affiliations
Background: In the Republic of Korea (Korea), the NVX-CoV2373 (Novavax) coronavirus disease 2019 (COVID-19) vaccination was administered to 18-year-olds and over from February 14, 2022. This study sought to assess the frequency and severity of reported adverse events following the Novavax COVID-19 vaccination in Korea.
Methods: Adverse events based on two national vaccine safety data were analyzed; the COVID-19 vaccination management system (CVMS) and the text-message survey (TMS).
Results: CVMS identified that the reporting rate of adverse events per 100,000 doses were lower after booster doses (84.0) than after dose 1 (254.6) or dose 2 (272.9); and in 65-year-olds and over (83.4) than in 18- to 64-year-olds (168.1). The TMS found that local and systemic adverse events were lower in 65-year-olds and over than in 18- to 64-year-olds (p < 0.001).
Conclusions: Overall, we identified no major safety issues and fewer adverse events following the Novavax COVID-19 vaccination among 65-year-olds and over in Korea.
Keywords: COVID-19; COVID-19 vaccines; Pharmacovigilance; Safety; Vaccination.
. 2023 Jun 27;S0264-410X(23)00780-6.
doi: 10.1016/j.vaccine.2023.06.077. Online ahead of print. Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
Seontae Kim[SUP] 1 [/SUP], Mijeong Ko[SUP] 2 [/SUP], Yesul Heo[SUP] 2 [/SUP], Yeon-Kyeng Lee[SUP] 2 [/SUP], Yunhyung Kwon[SUP] 2 [/SUP], Seok-Kyoung Choi[SUP] 2 [/SUP], Eunok Bahng[SUP] 2 [/SUP]
Affiliations
- PMID: 37422379
- PMCID: PMC10293897
- DOI: 10.1016/j.vaccine.2023.06.077
Background: In the Republic of Korea (Korea), the NVX-CoV2373 (Novavax) coronavirus disease 2019 (COVID-19) vaccination was administered to 18-year-olds and over from February 14, 2022. This study sought to assess the frequency and severity of reported adverse events following the Novavax COVID-19 vaccination in Korea.
Methods: Adverse events based on two national vaccine safety data were analyzed; the COVID-19 vaccination management system (CVMS) and the text-message survey (TMS).
Results: CVMS identified that the reporting rate of adverse events per 100,000 doses were lower after booster doses (84.0) than after dose 1 (254.6) or dose 2 (272.9); and in 65-year-olds and over (83.4) than in 18- to 64-year-olds (168.1). The TMS found that local and systemic adverse events were lower in 65-year-olds and over than in 18- to 64-year-olds (p < 0.001).
Conclusions: Overall, we identified no major safety issues and fewer adverse events following the Novavax COVID-19 vaccination among 65-year-olds and over in Korea.
Keywords: COVID-19; COVID-19 vaccines; Pharmacovigilance; Safety; Vaccination.